Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

compound, S110, activates an

important fetal hemoglobin biomarker in baboons, confirming the

product's ability to activate a specific silenced gene (Abstract 571).

An oral presentation by Donald Lavelle, Ph.D., of the University of

Illinois at Chicago, provided evidence that S110 increases fetal

hemoglobin and decreases DNA methylation in non-human primates and

cultured human erythroid progenitor cells (Poster 779). Finally the

prevention of cancer cell proliferation in non-clinical models, by the

Company's lead JAK2 kinase inhibitors was presented (Abstract 3560).

-- The Company announced that investigators dosed the first patient in a

multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-

targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470

in combination with several standard of care chemotherapy regimens,

including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel,

topotecan, and erlotinib. The trial is expected to enroll up to 105

patients at five study centers. The Phase 1b trial is an open label,

dose-escalation study designed to assess the safety and tolerability of

MP470 in combination with these standard of care chemotherapy regimens,

and to define the dose of MP470 to advance into Phase 2 combination

studies. Additionally, the Company will assess pharmacokinetic and

biomarker data from the study. The trial is open to chemotherapy naive

or treatment experienced patients with a variety of solid tumors

irrespective of previous lines of therapy.

Conference Call Information

SuperGen will host a conference call to discuss the results of the 2007 fourth quarter and annual financial results today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
... N.J., April 25 Osteotech, Inc.,(Nasdaq: OSTE ), ... for,regenerative medicine, announced today that the United States Food ... the Plexur,P(TM) Biocomposite for use in spinal applications as ... Previously, Osteotech received FDA clearance for,Plexur P(TM) for use ...
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... held April 30 - May 2, 2008, at ... Executive Officer, will,attend. His presentation is scheduled for ...
Cached Biology Technology:Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 2Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 3
(Date:4/24/2014)... Have you ever accidently missed a red light or ... a visible event that you passed by but totally ... for our attention, we can only be aware of ... Beckman Institute Postdoctoral Fellow at the University of Illinois. ... concentrating on obeying traffic signals." , But say there,s ...
(Date:4/24/2014)... attack plants, they often inject harmful proteins into ... natural defenses. However, in some plants, bacteria attack ... potential host. Now, researchers at the University of ... allows the bacteriaknown mostly for attacking tomatoesto invade ... anti-infective treatments that work with food-producing plants to ...
(Date:4/24/2014)... Alison Allan, PhD, a scientist at Western University and ... often spreads or metastasizes to the lung. , Breast ... number two cause of cancer-related deaths among women in ... radiation have a high success rate, but once the ... In particular, the lung is one of the most ...
Breaking Biology News(10 mins):Controlling brain waves to improve vision 2Controlling brain waves to improve vision 3Plants send out signals attracting harmful bacteria, MU study finds 2New study helps to explain why breast cancer often spreads to the lung 2
... The American Association for Cancer Research will host its ... Disparities from Sept. 18-21, 2011, in the Grand Hyatt ... will bring together scientists, survivors, doctors and others to ... treatment methods to better meet the needs of underserved ...
... have employed pheromone-baited bucket traps, canines to sniff out ... to eradicate the coconut rhinoceros beetle (CRB) on Guam ... to these tactics. USDA has given Guam an infusion ... rhino beetle population on island. Aubrey Moore, entomologist and ...
... of American Societies for Experimental Biology (FASEB) announced today ... (HCS). The executive leadership has retained FASEB to ... membership marketing, recruitment, and retention, as well as a ... William Stahl, PhD commented, "HCS is pleased to have ...
Cached Biology News:AACR to host conference on the science of cancer health disparities 2